By the evidence, the best treatment for chronic insomnia is cognitive behavioral therapy for insomnia (CBT-I). That is not a marketing claim; it is the conclusion of the American Academy of Sleep Medicine, the American College of Physicians and the European Sleep Research Society, each reviewing the trials independently.
But "best" deserves a straight comparison, so here is every option people actually reach for, rated the way the guidelines rate it.
At a glance
| Treatment | Guideline position | What the evidence shows |
|---|---|---|
| CBT-I | Strong recommendation (AASM); first-line for all adults (ACP); first-line in person or digitally (Europe) | About 19 minutes faster to fall asleep, 26 minutes less awake at night, 10 points higher sleep efficiency; gains persist after treatment |
| Sleeping pills | All fourteen AASM drug recommendations weak; generally short-term only | Similar to CBT-I in the short term; benefit generally lasts while taken |
| Melatonin | AASM suggests against for chronic insomnia | About 7 minutes faster to fall asleep, about 8 minutes more sleep |
| Sleep hygiene alone | AASM recommends against as a standalone treatment | Sensible background advice; not a treatment for chronic insomnia |
How each treatment is rated
CBT-I
Guideline status: the only strong recommendation in the AASM's behavioral guideline. First-line for all adults with chronic insomnia, per the American College of Physicians. First-line in Europe, delivered in person or digitally.
What it changes: pooled across trials, people fell asleep about 19 minutes faster, spent about 26 minutes less awake in the night, and gained about 10 percentage points of sleep efficiency. Total sleep time did not change significantly - what improves is how consolidated the night is.
How long it lasts: this is its biggest advantage. Gains shrink over the following year but persist after treatment ends, which is the main reason guideline committees put it first. What lasting improvement looks like in the data.
The catch: it takes work and several weeks, and the first weeks are often harder before they get easier. What CBT-I involves.
Sleeping pills
Guideline status: the AASM's guideline on insomnia medication makes fourteen drug recommendations. All fourteen are weak, on low or very low quality evidence. The American College of Physicians recommends CBT-I before medication. The European guideline limits hypnotics to short-term use, four weeks or less.
What it changes: in the short term, medication and CBT-I can look similar. The difference shows up later. In one double-blind trial in older adults, measured sleep efficiency rose from 81.4% to 88.9% with CBT, while the zopiclone group went from 82.3% to 81.5%. At six months the CBT group was at 90.1% and the medication group at 81.9%.
The catch: benefits generally last only as long as the medication is taken. That is not a reason to stop anything - it is a reason to have the conversation with your prescriber. The full comparison.
Melatonin
Guideline status: the AASM guideline suggests against melatonin for chronic insomnia.
What it changes: pooled trials found it shortened the time to fall asleep by about seven minutes and increased total sleep by about eight. Real, and small.
